Results 131 to 140 of about 11,074 (164)

Targeting Oncogenic Gene Fusions in Lung Cancer. [PDF]

Cancer J
Nie Y, Wilson FH.
europepmc   +1 more source

Long-term outcomes of ALK inhibitors in metastatic <i>ALK</i>-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data. [PDF]

Transl Lung Cancer Res
Ossato A, Damuzzo V, Del Bono L, Gasperoni L, Lupi T, Colicchio A, Gori S, Inno A.   +7 more
europepmc   +1 more source

Transformation of ALK-translocated lung adenocarcinoma to LCNEC under alectinib treatment - a case report and mini-review. [PDF]

Oncologist
Kim J, Stephan LU, Steinestel K, Tamal YA, Arndt A, Barck T.   +5 more
europepmc   +1 more source

Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report. [PDF]

Front Med (Lausanne)
Chen J, Lian Y, Lan Y, Chen C, Chen J, Zeng Z, Feng S, Wang M, Gao T.   +8 more
europepmc   +1 more source

Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. [PDF]

Int J Mol Med
Guo H, Li Y, Jin C, Qi X, Wang J, Li B, Wang C.   +6 more
europepmc   +1 more source

A High-Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK-Rearranged Non-Small Cell Lung Cancer. [PDF]

Pediatr Blood Cancer
Guerra AD, Evageliou NF, Batra V, Dalton KL, Ortel S, Ashraf U, Bhatti TR, States LJ, Surrey LF, Laetsch TW.   +9 more
europepmc   +1 more source

A natural language processing approach to determine whether streamlined health technology assessment for multi-indication medicines is feasible. [PDF]

PLOS Digit Health
Luc I, Carter D, Bergman E, Westman G, Merlin T.   +4 more
europepmc   +1 more source

Comparative effectiveness and cost-effectiveness of ALK-positive NSCLC sequential strategies under physician and patient preferences. [PDF]

Cost Eff Resour Alloc
Li H, Zhao M, Yin Y, Li J, Tang W.
europepmc   +1 more source

Safety recommendations for ALK tyrosine kinase inhibitors in non-small cell lung cancer: evidence from FAERS and CVARDD real-world databases. [PDF]

Front Oncol
Zhang Y, Zhang T, Yang Y, Zhang W, Ma Q, Li J, Li J, Yang X, Gong J, Wang X, Liang J.   +10 more
europepmc   +1 more source

Advanced ALK-EML4 fusion-positive non-small cell lung cancer with intraspinal metastases: a case report. [PDF]

Front Oncol
Lang J, Guo B, Han Q, Xiong Z.
europepmc   +1 more source